Strengthening Tumor-Informed MRD Assays with Standardized Analytical Validation

BLOODPAC Executive Director Lauren Leiman will moderate a panel discussion at the 16th World Clinical Biomarkers & CDx Summit focused on strengthening tumor-informed minimal residual disease (MRD) assays through standardized analytical validation.

The discussion will explore key considerations for defining intended use and aligning study designs with qualitative detection endpoints, designing precision studies across instruments, operators, and sites amid clinical sample scarcity, and establishing robust assay accuracy when orthogonal reference methods may be less sensitive than the MRD assay.

October 6, 2026 | 6:10–6:30 PM ET
Boston, MA

Moderator: Lauren Leiman
Panelists: Jon Baden, Angela Silverstro, Fernando Cruz-Guilloty, Nancy Krunic

Learn more about the event on the event website.